1.Total Laparoscopic Hysterectomy (TLH) : A Clinical Review of 300 Cases.
Yeon Ju KIM ; Boo Soo HA ; Beum Deuk LEE ; Jong Keun LEE ; Yong Seuk SON ; Yoon Won CHOUGH
Korean Journal of Obstetrics and Gynecology 2002;45(2):292-297
This clinical study was conducted to survey 300 cases of total laparoscopic hysterctomy (TLH) by the Department of Obstetrics and Gynecology of Boram Hospital in Ulsan, Korea from January, 2000 to June, 2001. TLH has been described in much of the recent literature. We analyzed 300 cases of TLH to evaluate the clinical data such as distribution of age, parity, clinical indication, previous operation history, type of surgery, operation time, weight of uterus, Hb change of post-operation first day and the complications of using this technique. The mean age of patients was 41.3. The mean parity of patients was 2.6. The clinical indications for TLH were myoma (72.3%), adenomyosis (11.3%), PID (5.3%), CIS (4%) and others (5.7%). The most previous operation was bilateral tubal ligation. Others were cesarean section, appendectomy. The most concomitant procedure with TLH was posterior colpoperineorrhaphy. Salpingo-oophorectomy and appendectomy were also carried out concomitantly. The mean operation time was 124 minutes. The mean weight of the uterus was 230 gm. The mean Hb change post-operation on the 1st day was 1.3g/dL. The complications of TLH were bleeding to need blood transfusion, ureteral injury and bladder injury. Thus this technique can be safely performed by skilled laparoscopists for properly selected patients but there is a need for prospective studies for comparision with various laparoscopic hysterctomies.
Adenomyosis
;
Appendectomy
;
Blood Transfusion
;
Cesarean Section
;
Female
;
Gynecology
;
Hemorrhage
;
Humans
;
Hysterectomy*
;
Korea
;
Myoma
;
Obstetrics
;
Parity
;
Pregnancy
;
Sterilization, Tubal
;
Ulsan
;
Ureter
;
Urinary Bladder
;
Uterus
2.The Effects of Recombinant Human Alpha-lnterferon on Epidemic Keratoconjunctivitis.
Jae Ho KIM ; Man Soo KIM ; Ha Beum LEE ; Jae Chan KIM ; Sung Won LEE
Journal of the Korean Ophthalmological Society 1992;33(1):39-48
The one hundred ninty three patients of epidemic keratoconjunctivitis (EKC) were treated with recombinant human alpha interferon (Re-Hu-INF-a eyedrop, 30,000IU/Vial, Cheil Foods and Chemicals Inc.) at kangnam St. Mary's Hospital, Catholic University Medical College, Chungang University Hospital, Kangdong Sacred Heart Hospital, Hallym University and Kims's Eye Clinic and the following results were obtained after at least 21 days follow-up. 1. The total patients of EKC were 266; 193 of patients were treated with INF and another 73 patients were treated with antibiotic eye drop only as a control group. The age ranged from 3 to 79 year-old and the average age were 29.6 in interferon group and 36.3 in control group. 2. There was no significant difference between two groups in number of eyes involved. The frequencey of infection route was family, swimming pool, and eye clinic order. Adenovirus was the most common causative agent according to the cytopathic effect of HeLa cell inoculation. 3. In most of cases, there was little symptomatic manifestation, if ever, malaise was the most common systemic symptom in both groups. 4. The symptomatic improvement after INF treatment Was began at 3.8 days in INF group comparing to 10.8 days in control group. In INF treated group, the subjective symptom was disappeared in 70.5% of patients within 4 days. But in control gorup, disappearance of subjective symptom was noted in only 17.8% of patients and the results were statistically significant. 5. The eariler INF treatment, the better improvement of EKC and the sign improved first was foreign body sensation. 6. There was little side effect of INF treatment, but ocular pain was occurred in 8% From these results, we suggest that recombinant human alpha interferon eyedrop in EKC treatment is effective and the earlier application is more effective especially.
Adenoviridae
;
Aged
;
Follow-Up Studies
;
Foreign Bodies
;
Heart
;
HeLa Cells
;
Humans*
;
Interferon-alpha
;
Interferons
;
Keratoconjunctivitis*
;
Sensation
;
Swimming Pools
3.The effects of ranitidine on T-lymphocyte subsets in septic patients.
Young Hyun CHO ; Woo Song HA ; Soon Tae PARK ; Soon Chan HONG ; Ho Seong HAN ; Jung In JE ; Sang Beum KIM ; Ok Jae LEE
Journal of the Korean Surgical Society 1993;45(4):603-610
No abstract available.
Humans
;
Ranitidine*
;
T-Lymphocyte Subsets*
;
T-Lymphocytes*
4.The Cutcome of Living-related Renal Transplantation with Previously Positive but Currently Negative HLA Crossmatching.
Jang Han LEE ; Jong Ha PARK ; Jeong Min CHOI ; Jea Pil YOON ; Seoung Ki AHN ; Soo hi KIM ; Hung Beum OH ; Jea Yon JANG ; Su Kil PARK
Korean Journal of Nephrology 2005;24(3):448-454
PURPOSE: Previously positive but currently negative HLA crossmatching is considered to be a risk factor not in the first renal transplantation but in the second renal transplantation. The aim of this study is to analyse the outcome of living-related renal transplantation with previously positive but currently negative HLA crossmatching. METHODS: The results of first HLA crossmatching, demographic characteristics, the outcome of renal trasplantation were examined in four patients undergoing renal transplantation with previously positive but currently negative HLA crossmatching. RESULTS: The acute rejection was occurred in 3 patients. Azotemia was improved with the immunosuppressive therapy containing tacrolimus. There were no graft failures in four patients for 1 year. In the first HLA crossmatching, anti-human globulin T cell HLA crossmatching was positive in all patients with acute rejection. The period that positive HLA crossmatchings were converted to negative was longer in patients with acute rejections than without acute rejections (177 days vs 22 days). CONCLUSION: There were 3 acute rejections in 6 patients undergoing living related renal transplantations with previously positive and current negative HLA crossmatching. There were no graft failure for 1 year.
Azotemia
;
Humans
;
Kidney Transplantation*
;
Risk Factors
;
Tacrolimus
;
Transplants